Keywords
Epithelial ovarian cancer, hysterectomy, histological type, endometriosis, menopausal
hormone therapy
Posted Date: November 1st, 2022
DOI: https://doi.org/10.21203/rs.3.rs-2173859/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Version of Record: A version of this preprint was published at Cancer Epidemiology on June 1st, 2023.
See the published version at https://doi.org/10.1016/j.canep.2023.102359.
Page 2/15
Abstract
Purpose
This nationwide, register-based case-control study investigated the association between hysterectomy
and risk of epithelial ovarian cancer according to histology and by history of endometriosis and MHT
use.
Methods
From the Danish Cancer Registry, all women registered with epithelial ovarian cancer during 1998 ‒ 2016
were identied (n = 6,738). Each case was sex- and age-matched to 15 population controls using risk-set
sampling. Information on previous hysterectomy on benign indication and potential confounders was
retrieved from nationwide registers. Conditional logistic regression was used to calculate odds ratios
(ORs) with 95% condence intervals (CIs) for the association between hysterectomy and ovarian cancer
according to histology, endometriosis, and use of MHT.
Results
Hysterectomy was not associated with risk of epithelial ovarian cancer overall (OR = 0.97; 95% CI 0.88 ‒
1.06) but was associated with reduced risk of clear cell ovarian cancer (OR = 0.47; 95% CI 0.28 ‒ 0.78). In
stratied analyses, decreased ORs associated with hysterectomy were seen in women with
endometriosis (OR = 0.73; 95% CI 0.50 ‒ 1.09) and in non-users of MHT (OR = 0.87; 95% CI 0.76 ‒ 1.00).
Conclusion
Hysterectomy was not associated with epithelial ovarian cancer overall but with reduced risk of clear cell
ovarian cancer. Our ndings may suggest a reduced risk of ovarian cancer after hysterectomy in women
with endometriosis and in MHT non-users, but the statistical precision of our results did not allow rm
conclusions.
what Does This Study Adds To The Clinical Work
We found an inverse association between hysterectomy and the risk of clear cell ovarian cancer, and a
potential protection against ovarian cancer in women with endometriosis and in non-users of
menopausal hormone-therapy.
Introduction
Page 3/15
Worldwide, ovarian cancer is the eighth most common cancer in women with an age-standardized
incidence rate of 6.6 cases per 100,000 person-years [1]. Approximately 95% of ovarian cancers are of
epithelial origin and are primarily classied into ve main types; high- and low-grade serous,
endometrioid, clear cell, and mucinous ovarian cancer [2]. High-grade serous carcinoma is the most
common histological type accounting for approximately 70% of ovarian carcinomas [2].
It has been suggested that hysterectomy protects against ovarian cancer by blocking transfer of
carcinogenic agents, and retrograde menstruation or endometriosis travelling through the female genital
tract [3–5]. A number of studies have investigated the association between hysterectomy and risk of
ovarian cancer with inconsistent ndings [4–15]. A meta-analysis observed a time-dependent trend in
ndings and pointed out that one explanation could be changes over time in use of menopausal
hormone therapy (MHT) [13]. MHT is known to increase the risk of ovarian cancer moderately [16, 17],
and is more commonly used among hysterectomized women [18], which might explain why a few recent
observational studies have reported that the association between hysterectomy and ovarian cancer risk
differs by use of MHT [8–10]. Other studies have reported that the association between hysterectomy
and ovarian cancer varies by tumor histology [5, 6, 9, 12], and history of endometriosis [6, 10, 14].
Concomitant removal of the fallopian tubes and/or ovaries at time of hysterectomy are also important
factors to consider. Recent research has revealed that the precursor lesion of high-grade serous
carcinoma originates in the fallopian tube as serous tubal intraepithelial carcinoma lesions [19], and that
bilateral salpingectomy therefore reduces the risk of ovarian cancer [3, 7].
Clarication of the impact of hysterectomy on the risk of ovarian cancer may elucidate the pathogenesis
of the disease but it is also important from a clinical point of view to determine whether the procedure
protects against ovarian cancer, and identify potential target groups who benet the most.
The aim of this nationwide register-based case-control study is to evaluate the association between
hysterectomy on benign indication and the risk of ovarian cancer. Our analyses are stratied by
histologic subtype of ovarian cancer and investigate whether endometriosis and MHT may be effect
modiers for the association between hysterectomy and the risk of ovarian cancer.
Methods
This nationwide, register-based case-control study has previously been described in detail [3], and has
since been updated with four additional years. In Denmark, the Civil Registration System assigns all
Danish citizens a personal identication number, which enables accurate linkage between the different
registers. The register also contains information on dates of death, and migration to and from Denmark
[20].
Study population
Cases were identied in the Danish Cancer Registry, which contains information on cancer diagnoses in
Denmark since 1943 and with mandatory reporting of new cancer cases since 1987 [21]. Since 2004,
Page 4/15
cancer cases have been registered using the 10th revision of the International Classication of Diseases
(ICD-10) and the 3rd revision of the International Classication of Diseases for Oncology (ICD-O-3), and
codes for cancer cases registered during 1978 ‒ 2003 have been converted to ICD-10 and ICD-O-3. Cases
were identied in the Cancer Registry by ICD-10 DC56. We required that cases were aged 40 ‒ 79 years at
the index date, dened as the date of diagnosis, without previous cancer, and with a rst diagnosis of
histologically veried epithelial ovarian cancer during 1998 ‒ 2016. Ovarian cancer cases were classied
according to the ICD-O-3 morphology code into serous, endometrioid, clear cell, mucinous and other
(Supplementary Table S1). Information on grade was not available.
Each case was matched by month and year of birth to 15 control women identied in the Civil
Registration System using risk set sampling. Controls were not allowed to have a history of bilateral
oophorectomy/salpingo-oophorectomy or cancer (except non-melanoma skin cancer) at the time the
corresponding case was diagnosed, i.e., index date. Women were eligible as controls before becoming
cases.
Information on exposure
Information on hysterectomy up until one year prior to index date was retrieved from the Danish National
Patient Register, which has registered all diagnoses and surgical procedures performed during
hospitalizations since 1977, and during outpatient visits since 1995 [22]. From 1977 to 1993, all
diagnoses are coded according to ICD-8, and from 1994 diagnoses are coded according to ICD-10. All
surgical procedures are classied according to the Danish Classication of Surgical Procedures up until
the end of 1995, and afterwards according to the Nordic Classication of Surgical Procedures.
Information on covariates
Information on use of oral contraceptives and MHT was obtained from the Danish National Prescription
Registry, where individual-level information on all prescription drugs dispensed at pharmacies in
Denmark since 1995 are registered [23], and classied by the Anatomical Therapeutic Chemical Index
[24]. From the Danish National Patient Register, information since 1977 on endometriosis, tubal ligation,
and other gynecological surgical procedures including salpingectomies and oophorectomies up until one
year prior to index date was obtained. Parity was derived from the Danish Fertility Database, which
contains information on reproductive variables for all women aged 13 ‒ 49 years in Denmark from 1980
and onwards [25].
Statistical analyses
We used conditional logistic regression to calculate age-matched and multivariable adjusted odds ratios
(ORs) and 95% condence intervals (CIs) for the association between hysterectomy and risk of epithelial
ovarian cancer overall and stratied according to histologic subtype. Potential confounders were
selected a priori based on evidence of risk factors for ovarian cancer and availability in the registers. The
model was adjusted for age (by design), parity, endometriosis, tubal ligation, other gynecological surgical
Page 5/15
procedures (tubal ligation, unilateral/bilateral salpingectomy, unilateral oophorectomy, and unilateral
salpingo-oophorectomy), and use of oral contraceptives and MHT.
To investigate effect modication by endometriosis and MHT use, we performed stratied analysis using
logistic regression without the matching, but with adjustment for the matching factors (age and calendar
year). All analyses were performed using the statistical software R version 4.1.0.
Use of register data for this study was approved by the Danish National Board of Health Data (FSEID-
4295). In agreement with the General Data Protection Regulation, the present study is registered in the
Danish Cancer Society’s internal list of projects dealing with personalized data (journal number: 2019-
DCRC-0054). All data related to the study are stored at the Danish Cancer Society Research Center’s
project database at Statistics Denmark (project number 704327), and the Danish Cancer Society is
responsible for the data stored at this project database. The data that support the information of this
manuscript were accessed remotely on a secure platform at Statistics Denmark (www.dst.dk).
According to Danish laws and regulations, individual-level sensitive data can only be made available for
researchers who full legal requirements for accessing personal sensitive data.
Results
The study population included 6,738 women with epithelial ovarian cancer and 101,070 matching
controls. The majority of cases were 60 ‒ 79 years old at diagnosis and the most common histologic type
of tumor was serous (58.7%) (Table 1). Hysterectomy was reported in 588 (8.7%) cases and in 9,289
(9.2%) controls. Cases (18.1%) were more likely to be nulliparous compared with controls (12.7%).
Endometriosis was diagnosed in 130 (1.9%) cases and in 1,665 (1.6%) controls. Finally, ever use of MHT
was slightly more common among cases (35.6%) compared with controls (33.2%).
Page 6/15
Table 1
Characteristics of women with epithelial ovarian cancer and matching controls
Cases Controls
(n = 101,070)(n = 6,738)
Characteristics n % n %
Histology
Serous 3,953 (58.7) —
Mucinous 565 (8.4) —
Endometrioid 596 (8.8) —
Clear cell 328 (4.9) —
Other 1,296 (19.2) —
Age at diagnosis / index date (years)
40–49 794 (11.8) 11,910 (11.8)
50–59 1,707 (25.3) 25,605 (25.3)
60–69 2,270 (33.7) 34,050 (33.7)
70–79 1,967 (29.2) 29,505 (29.2)
Hysterectomy
No 6,150 (91.3) 91,781 (90.8)
Yes 588 (8.7) 9,289 (9.2)
Age at hysterectomy (years)
No hysterectomy 6,150 (91.3) 91,781 (90.8)
<50 459 (6.8) 7,036 (7.0)
≥ 50 129 (1.9) 2,253 (2.2)
Parity
Nulliparous 1,218 (18.1) 12,866 (12.7)
One 1,311 (19.5) 17,047 (16.9)
Two 2,631 (39.0) 42,629 (42.2)
Three or more 1,578 (23.4) 28,528 (28.2)
Endometriosis
No 6,608 (98.1) 99,405 (98.4)
Page 7/15
Cases Controls
(n = 101,070)(n = 6,738)
Yes 130 (1.9) 1,665 (1.6)
Oral contraceptives
No 6,309 (93.6) 90,667 (89.7)
Yes 429 (6.4) 10,403 (10.3)
Menopausal hormone therapy
No ( 2 prescriptions) 2,396 (35.6) 33,603 (33.2)
Tubal ligation
No 6,411 (95.1) 94,775 (93.8)
Yes 327 (4.9) 6,295 (6.2)
Other gynecological surgical proceduresa
No 6,563 (97.4) 96,969 (95.9)
Yes 175 (2.6) 4,101 (4.1)
Hysterectomy was not associated with the overall risk of epithelial ovarian cancer (OR = 0.97; 95% CI
0.88 ‒ 1.06) (Table 2). When the analysis was stratied according to tumor histology, we observed a
signicantly reduced risk of clear cell ovarian cancer after hysterectomy (OR = 0.47; 95% CI 0.28 ‒ 0.78).
The OR for mucinous ovarian cancer was decreased (OR = 0.80; 95% CI 0.56 ‒ 1.14), whereas an elevated
OR was observed for endometrioid ovarian cancer (OR = 1.29; 95% CI 0.97 ‒ 1.72). Finally, hysterectomy
was associated with neutral ORs for serous (OR = 1.00; 95% CI 0.89 ‒ 1.13) and other epithelial ovarian
cancers (OR = 0.96; 95% CI 0.76 ‒ 1.20).
Page 8/15
Table 2
Hysterectomy and risk of epithelial ovarian cancer stratied according to histologic subtype
Cases Controls Age-adjusted Adjusteda
Histologicsubtype N (%) N (%) OR 95% CI OR 95% CI
All epithelial
Nohysterectomy 6,150 (91.3) 91,781 (90.8) Ref. Ref.
Hysterectomy 588 (8.7) 9,289 (9.2) 0.94 (0.86 ‒1.03) 0.97 (0.88 ‒1.06)
Serous
Nohysterectomy 3,585 (90.7) 53,677 (90.5) Ref. Ref.
Hysterectomy 368 (9.3) 5,618 (9.5) 0.98 (0.88 ‒1.10) 1.00 (0.89 ‒1.13)
Mucinous
Nohysterectomy 529 (93.6) 7,715 (91.0) Ref. Ref.
Hysterectomy 36 (6.4) 760 (9.0) 0.69 (0.49 ‒0.97) 0.80 (0.56 ‒1.14)
Endometrioid
Nohysterectomy 531 (89.1) 8,156 (91.2) Ref. Ref.
Hysterectomy 65 (10.9) 784 (8.8) 1.28 (0.98 ‒1.67) 1.29 (0.97 ‒1.72)
Clear cell
Nohysterectomy 309 (94.2) 4,466 (90.8) Ref. Ref.
Hysterectomy 19 (5.8) 454 (9.2) 0.60 (0.37 ‒0.97) 0.47 (0.28 ‒0.78)
Other
Nohysterectomy 1,196 (92.3) 17,767 (91.4) Ref. Ref.
Hysterectomy 100 (7.7) 1,673 (8.6) 0.89 (0.72 ‒1.10) 0.96 (0.76 ‒1.20)
Abbreviations: OR, Odds ratio; CI, Condence interval; Ref., Reference
Page 9/15
Cases Controls Age-adjusted Adjusteda
aAdjusted for age (by design), calendar year (by design), parity (categorical), tubal ligation,endometriosis, other gynaecological surgical procedures, oral contraceptive use, and use ofmenopausal hormone therapy.
Table 3 presents the analysis stratied according to occurrence of endometriosis. In women with a
previous diagnosis of endometriosis, hysterectomy was associated with a reduced OR for ovarian cancer
(OR = 0.73; 95% CI 0.50 ‒ 1.09), whereas the association between hysterectomy and ovarian cancer in
patients without a diagnosis of endometriosis was close to unity (OR = 0.99; 95% CI 0.90 ‒ 1.08).
Table 3
Hysterectomy and risk of epithelial ovarian cancer by history of endometriosis
Age-adjusted
OR (95% CI)
Adjusteda
OR (95% CI)
No endometriosis
No hysterectomy Ref. Ref.
Hysterectomy 1.04 (0.94 ‒ 1.14) 0.99 (0.90 ‒ 1.08)
Endometriosis
No hysterectomy Ref. Ref.
Hysterectomy 0.75 (0.51 ‒ 1.12) 0.73 (0.50 ‒ 1.09)
Abbreviations: OR, Odds ratio; CI, Condence interval; Ref., Reference
aAdjusted for age, calendar year, parity (categorical), tubal ligation, other gynaecological surgicalprocedures, oral contraceptive use and use of menopausal hormone therapy.
Finally, we examined the effect of hysterectomy stratied according to use of MHT. The ORs for the
association between hysterectomy and ovarian cancer were 0.87 (95% CI 0.76 ‒ 1.00) in women who
never used MHT and 1.05 (95% CI 0.93 ‒ 1.19) in women who had redeemed minimum two prescriptions
of MHT before index date (Table 4).
Page 10/15
Table 4
Hysterectomy and risk of epithelial ovarian cancer by ever use of menopausal hormone therapy (MHT)
Age-adjusted
OR (95% CI)
Adjusteda
OR (95% CI)
Non-use of MHT
No hysterectomy Ref. Ref.
Hysterectomy 0.90 (0.78 ‒ 1.03) 0.87 (0.76 ‒ 1.00)
Ever-use of MHT
No hysterectomy Ref. Ref.
Hysterectomy 1.08 (0.95 ‒ 1.22) 1.05 (0.93 ‒ 1.19)
OR: Odds ratio; CI: Condence interval; Ref.: Reference
aAdjusted for age, calendar year, parity (categorical), tubal ligation, other gynaecological surgicalprocedures, and use of oral contraceptives.
Discussion
In this study hysterectomy was not associated with the risk of epithelial ovarian cancer overall but
seemed to reduce risk of the clear cell type. In women with endometriosis and in women not using MHT,
reduced odds for ovarian cancer after hysterectomy were observed.
In line with our ndings, recent studies have found no association between hysterectomy and risk of
ovarian cancer overall [6, 10, 15], and a meta-analysis reported a pooled OR of 0.97 (95% CI: 0.83–1.12)
based on data from 18 case-control studies published between 2000 and 2017 [5]. In contrast, data from
two earlier meta-analyses published in 2012 [4], and 2013 [13], respectively, suggested that hysterectomy
was associated with a lower risk of ovarian cancer. Both meta-analyses reported signicant
heterogeneity between the included studies primarily explained by median year of ovarian cancer
diagnosis, where studies published before 2000 indicated a lower risk of ovarian cancer following
hysterectomy, whereas studies published after 2000 did not. The authors speculated that the temporal
change in the association between hysterectomy and ovarian cancer risk could in part be attributed to
increasing use of MHT over calendar time in hysterectomized women [13].
MHT is more commonly prescribed to hysterectomized women than to non-hysterectomized women
[18], and is associated with a moderately increased ovarian cancer risk [16, 17]. In accordance, a recent
study from the Ovarian Cancer Association Consortium (OCAC) found that adjustment for duration of
MHT use affected the association between hysterectomy and ovarian cancer risk markedly [10]. A case-
control study including 614 African-American women with ovarian cancer reported that hysterectomy
decreased the risk of epithelial ovarian cancer (OR = 0.65, 95% CI: 0.46 ‒ 0.92) in never users of estrogen-
Page 11/15
only MHT, whereas increased odds was observed among users [8]. Moreover, data from the Nurses’
Health Study also showed that hysterectomy was associated with decreased odds for ovarian cancer
only in women who had never used MHT (hazard ratio (HR) = 0.81, 95% CI: 0.54 ‒ 1.20) [9], which is in line
with our ndings.
Ovarian cancer is a heterogeneous disease and the etiology of the different subtypes may differ.
Therefore, it is also suggested that the association between hysterectomy and ovarian cancer may vary
according to the histological types of epithelial ovarian cancer [5, 6, 9]. Endometrioid and clear cell types
are strongly associated with endometriosis [26]. By preventing menstruation or endometriosis from
retrograde transport through the female genital tract, hysterectomy may protect primarily against those
types of ovarian cancer. A meta-analysis pooling data from four case-control studies with information on
tumor histology reported that hysterectomy was associated with a statistically signicant risk reduction
for endometrioid/clear cell ovarian cancer (OR = 0.70, 95% CI: 0.51 ‒ 0.94) [5]. The OR for mucinous
ovarian cancer was reduced but statistically not signicant and there was no association between
hysterectomy and serous ovarian cancer [5]. Other studies not included in the meta-analysis by Huo et al.
[5] have also reported that hysterectomy protected against clear cell ovarian cancer [12] or that risk
estimates for endometrioid and/or clear cell ovarian cancer pointed in the protective direction without
statistical signicance [6, 9, 12]. Risk estimates for mucinous ovarian cancer are also reported
statistically non-signicantly decreased in several studies [6, 9, 12], whereas a null-association with
serous ovarian cancer is most often observed [6, 9, 12]. Our results are consistent with the majority of
previous recent studies, as we also found that hysterectomy was not associated with serous ovarian
cancer but protected against clear cell ovarian cancer. However, our data showed increased odds for
endometrioid ovarian cancer after hysterectomy. We have no denite explanation for this nding but
misclassication may have played a role. Cases in our study go back to 1998 and some of the tumors
that were diagnosed as endometrioid ovarian cancers may have been classied as high-grade serous
carcinomas today based on their immunoprole [27]. The association between hysterectomy and
endometrioid ovarian cancer may also be affected by unmeasured confounding. Although our study was
based on high-quality nationwide registers, registration of potential confounders such as endometriosis
may not be complete.
Our ndings in stratied analysis showing reduced odds for ovarian cancer after hysterectomy in women
with endometriosis is compatible with reports from previous studies [6, 10, 14]. One study with pooled
information from four US population-based case-control studies reported that hysterectomy was
associated with statistically non-signicantly decreased odds for ovarian cancer (OR = 0.69, 95% CI:
0.38 ‒ 1.24) in women with endometriosis, whereas this was not found in women without endometriosis
(OR = 1.02, 95% CI: 0.86 ‒ 1.23) [14]. In addition, an Australian register-based cohort study reported
substantially decreased risk of ovarian cancer (HR = 0.17, 95% CI: 0.12 ‒ 0.24) after hysterectomy in
women with endometriosis [6], and OCAC data also showed that hysterectomy statistically signicantly
reduced the risk of ovarian cancer in women with endometriosis (OR = 0.69, 95% CI 0.48 ‒ 0.99) [10].
Although hysterectomy, as previously discussed, may prevent retrograde transport of endometriosis, the
Page 12/15
observed protective effect of hysterectomy on ovarian cancer risk among women with endometriosis
may also be explained by removal of endometriotic lesions at the time of hysterectomy.
One of the main strengths of our study is the large sample size including more than 6,700 women with
ovarian cancer, making it possible to investigate associations with histologic subtypes of ovarian cancer.
Data were derived from nationwide registers with no risk of selection or recall bias. The registers contain
virtually complete and continuously updated data on surgical procedures, diagnoses, and drug use. The
register-based design of our study thereby enabled us to ensure that all control women had at least one
intact ovary and provided us with information on important potential confounding factors such as MHT
use and endometriosis.
Our study also has some limitations. Although all of our cases were histologically veried, we did not
perform a central pathology review of the ovarian tumors, and there may therefore be some degree of
misclassication, especially affecting those cancers diagnosed in the early part of our study period.
Moreover, we did not have information on tumor grade which precluded us from differentiating between
low and high-grade serous carcinomas. Finally, left truncation of prescription data may have led to
misclassication of MHT use among those women who initiated MHT before 1995, and although the
Danish National Patient Register was established earlier (1977), information on hysterectomy and
endometriosis may be incomplete.
It is important to know whether to recommend hysterectomy or not when it comes to the risk of ovarian
cancer, and due to the shift in ndings over time, new studies are required to clarify this. In our study,
hysterectomy does not protect against ovarian cancer overall, but a potentially decreased risk is
observed in women with endometriosis and in non-users of MHT.
In this nationwide, register-based case-control study there was no association between hysterectomy
and risk of ovarian cancer overall, but the analysis by histologic subtype revealed a reduced risk of clear
cell ovarian cancer. Data also showed reduced odds for ovarian cancer after hysterectomy in women
with endometriosis and in women not using MHT, albeit not statistically signicant. The statistical
precision of our results do not allow rm conclusions but combined with ndings from other recent
studies, they suggest that hysterectomy may be protective against ovarian cancer in these groups of
women.
Declarations
Author contribution
L.L. Ring: Protocol/project development, data analysis, manuscript writing/editing
L. Baandrup: Protocol/project development, data analysis, manuscript writing/editing
M. Gottschau: Protocol/project development, data analysis, manuscript writing/editing
Page 13/15
C. Dehlendorff: Data collection or management, data analysis, manuscript writing/editing
L. Mellemkjær: Protocol/project development, data analysis, manuscript writing/editing
S.K. Kjaer: Protocol/project development, data analysis, manuscript writing/editing
Funding
This work was supported by the Mermaid project [Mermaid 3]. The funding sources had no role in the
design and conduct of the study; collection, management, analysis, and interpretation of the data;
preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Competing Interests
Lene Mellemkjær has an immediate family member employed at Novo Nordisk, and has an immediate
family member who owns stocks in Novo Nordisk. All other authors declare no conicts of interest.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer
Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185
Countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
2. Prat J, D'Angelo E, Espinosa I (2018) Ovarian carcinomas: at least ve different diseases with
distinct histological features and molecular genetics. Hum Pathol 80:11–27.
https://doi.org/10.1016/j.humpath.2018.06.018
3. Madsen C, Baandrup L, Dehlendorff C, Kjaer SK (2015) Tubal ligation and salpingectomy and the risk
of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta
Obstet Gynecol Scand 94:86–94. https://doi.org/10.1111/aogs.12516
4. Rice MS, Murphy MA, Tworoger SS (2012) Tubal ligation, hysterectomy and ovarian cancer: A meta-
analysis. J Ovarian Res 5:13. https://doi.org/10.1186/1757-2215-5-13
5. Huo X, Yao L, Han X, Li W, Liu J, Zhou L, Gou Y, Yang K, Liu H (2019) Hysterectomy and risk of
ovarian cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 299:599–607.
https://doi.org/10.1007/s00404-018-5020-1
. Dixon-Suen SC, Webb PM, Wilson LF, Tuesley K, Stewart LM, Jordan SJ (2019) The Association
Between Hysterectomy and Ovarian Cancer Risk: A Population-Based Record-Linkage Study. J Natl
Cancer Inst 111:1097–1103. https://doi.org/10.1093/jnci/djz015
7. Falconer H, Yin L, Gronberg H, Altman D (2015) Ovarian cancer risk after salpingectomy: a
nationwide population-based study. J Natl Cancer Inst 107. https://doi.org/10.1093/jnci/dju410
. Peres LC, Alberg AJ, Bandera EV et al (2017) Premenopausal Hysterectomy and Risk of Ovarian
Cancer in African-American Women. Am J Epidemiol 186:46–53.
https://doi.org/10.1093/aje/kwx055
Page 14/15
9. Rice MS, Hankinson SE, Tworoger SS (2014) Tubal ligation, hysterectomy, unilateral oophorectomy,
and risk of ovarian cancer in the Nurses' Health Studies. Fertil Steril 102:192–8e3.
https://doi.org/10.1016/j.fertnstert.2014.03.041
10. Khoja L, Weber RP, Australian Ovarian Cancer Study G et al (2022) Endometriosis and menopausal
hormone therapy impact the hysterectomy-ovarian cancer association. Gynecol Oncol 164:195–201.
https://doi.org/10.1016/j.gyno.2021.10.088
11. Darelius A, Kristjansdottir B, Dahm-Kahler P, Strandell A (2021) Risk of epithelial ovarian cancer Type
I and II after hysterectomy, salpingectomy and tubal ligation-A nationwide case-control study. Int J
Cancer 149:1544–1552. https://doi.org/10.1002/ijc.33714
12. Wentzensen N, Poole EM, Trabert B et al (2016) Ovarian Cancer Risk Factors by Histologic Subtype:
An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol 34:2888–2898.
https://doi.org/10.1200/JCO.2016.66.8178
13. Jordan SJ, Nagle CM, Coory MD, Maresco D, Protani MM, Pandeya NA, Balasubramaniam KD, Webb
PM (2013) Has the association between hysterectomy and ovarian cancer changed over time? A
systematic review and meta-analysis. Eur J Cancer 49:3638–3647.
https://doi.org/10.1016/j.ejca.2013.07.005
14. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT (2004) Oral contraceptive
use, reproductive history, and risk of epithelial ovarian cancer in women with and without
endometriosis. Am J Obstet Gynecol 19:733–740. https://doi.org/10.1016/j.ajog.2004.03.035
15. Taylor JA, Burnell M, Ryan A et al (2022) Association of hysterectomy and invasive epithelial ovarian
and tubal cancer: a cohort study within UKCTOCS. BJOG 129:110–118.
https://doi.org/10.1111/1471-0528.16943
1. Morch LS, Lokkegaard E, Andreasen AH, Kjaer SK, Lidegaard O (2009) Hormone therapy and ovarian
cancer. JAMA 302:298–305. https://doi.org/10.1001/jama.2009.1052
17. Tsilidis KK, Allen NE, Key TJ et al (2011) Menopausal hormone therapy and risk of ovarian cancer in
the European prospective investigation into cancer and nutrition. Cancer Causes Control 22:1075–
1084. https://doi.org/10.1007/s10552-011-9782-z
1. Million Women Study C (2002) Patterns of use of hormone replacement therapy in one million
women in Britain, 1996–2000. BJOG 109:1319–1330. https://doi.org/10.1016/s1470-
0328(02)02914-2
19. Shih IM, Wang Y, Wang TL (2021) The Origin of Ovarian Cancer Species and Precancerous
Landscape. Am J Pathol 191:26–39. https://doi.org/10.1016/j.ajpath.2020.09.006
20. Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39(7 Suppl):22–
25. https://doi.org/10.1177/1403494810387965
21. Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39(7 Suppl):42–45.
https://doi.org/10.1177/1403494810393562
22. Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public
Health 39(7 Suppl):30–33. https://doi.org/10.1177/1403494811401482
Page 15/15
23. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J
Public Health 39(7 Suppl):38–41. https://doi.org/10.1177/1403494810394717
24. WHO Collaborating Centre for Drug Statistics Methofology (2022)
https://www.whocc.no/atc_ddd_index/. Accessed 11 October 2022
25. Blenstrup LT, Knudsen LB (2011) Danish registers on aspects of reproduction. Scand J Public Health
39(7 Suppl):79–82. https://doi.org/10.1177/1403494811399957
2. Kurman RJ, Shih Ie M (2016) The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and
Expanded. Am J Pathol. https://doi.org/10.1016/j.ajpath.2015.11.011. 186:733 – 47
27. Gilks CB(2010) Molecular abnormalities in ovarian cancer subtypes other than high-grade serous
carcinoma. J Oncol 2010:740968. https://doi.org/10.1155/2010/740968
Supplementary Files
This is a list of supplementary les associated with this preprint. Click to download.
SupplementaryMaterial.docx
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.